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Course of neuromyelitis optica during inadvertent
pregnancy in a patient treated with rituximab
HL Pellkofer1, C Suessmair1, A Schulze2, R Hohlfeld1 and T Kuempfel1
In neuromyelitis optica (NMO), the monoclonal B-cell antibody rituximab is a therapeutic option.
Little is known about the course of NMO and the safety of rituximab during pregnancy. In this
study, we report the clinical course of a patient with NMO after application of rituximab 1 week
before inadvertent conception. Mother and child did not experience any adverse event, and the post-
partum development of the baby was completely normal up to 15 months. Clinical course of NMO
was stable during the entire pregnancy. This case illustrates a favorable outcome in a pregnant NMO
patient and her child after therapy with rituximab. Multiple Sclerosis 2009; 15: 1006–1008.
http://msj.sagepub.com
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Introduction
Neuromyelitis optica (NMO) is an inflammatory
disorder of the central nervous system that is classi-
cally restricted to the optic nerves and spinal cord.
New histopathological and serological findings
point to a pathogenic role of serum autoantibodies
directed against the aquaporin-4 (AQP4) water
channel. Treatment usually relies on immunosup-
pressant medications, such as azathioprine, mitox-
antrone, mycophenolate mofetil, and more
recently, rituximab, a monoclonal anti-CD20+ B-
cell antibody [1].
Little is known about the course of NMO and the
safety of rituximab during pregnancy. Although the
substance had not shown fetotoxicity in nonhu-
man primates, human data are limited. There are
only a few case reports on the effects of rituximab
during pregnancy in patients with B-cell lymphoma
who generally had a favorable outcome of their
pregnancy despite rituximab treatment. Because
rituximab is a chimeric antibody of the IgG isotype,
it crosses the placenta from week 16 onwards and,
therefore, may deplete B-cells of both mother and
child [2].
In this study, we report the clinical course of
NMO in a pregnant woman who received rituximab
1 week before inadvertent conception.
Case report
This previously healthy 19-year-old woman devel-
oped optic neuritis and myelitis in 2001. Cerebro-
spinal fluid investigations revealed eight lympho-
cytes/μL and elevated protein (78 mg/dL) without
oligoclonal banding. IgG titer to measles, rubella,
and varicella zoster, (MRZ reaction) were within
normal range. Magnetic resonance imaging (MRI)
of the spinal cord showed an extensive T2-
hyperintensive lesion extending over five vertebral
segments, whereas the cranial MRI was completely
normal. NMO was diagnosed according to the diag-
nostic criteria of Wingerchuk, et al. [3]. Subse-
quently she was tested positive for AQP4-abs.
After initial stabilization during 5 years of ther-
apy with azathioprine, she experienced several
relapses in 2006. At this time she had a persistent
visual deficit on the right eye (visual acuity right
eye 0.63, left eye 1.3), a moderate paraparesis and
a marked decrease in proprioception (EDSS 4.5).
Azathioprine was discontinued, and treatment
with rituximab was started in February and March
2007 (1 g rituximab twice with a 2-week interval).
Rituximab led to complete depletion of CD19+ B-
cells (Figure 1). Four weeks later, the patient had a
positive pregnancy test. The date of her inadvertent
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conception was determined as 1 week after the sec-
ond rituximab infusion.
CD19+ B-cells remained depleted, and the clini-
cal course was stable during the entire pregnancy.
Fetal development was regularly monitored and
was normal during pregnancy. At delivery on
December 25, 2007, B-cells were still absent in the
mother, whereas the child had completely normal
B-cell counts. Serum IgG levels of mother and child
were within normal limits. All clinical examinations
of the newborn were normal; routine vaccinations
could be given without side effects. Ten days post-
partum, the mother had a new relapse of myelitis.
CD19+ B-cells were not detectable at this time
point. Treatment with high-dose corticosteroids
was followed by remission of her symptoms. Two
months later, she had another relapse. CD19+ B-
cells were detectable again, and a second course of
rituximab was given in April 2008 (two times, 1 g
two weeks apart). The patient has remained stable
until now (Figure 1). Further development of the
baby was completely normal.
Discussion
Because NMO is rare, data on course and outcome
of pregnancies of NMO patients are limited to a few
case reports [4]. All previously described patients
had severe exacerbations of NMO during preg-
nancy. It is known that pregnancy leads to a pro-
gressive shift from Th1-mediated immune response
to increased Th2-mediated immunity [5] due to
increasing levels of progesterone and estrogens.
This could explain why pregnancy ameliorates
some autoimmune diseases such as multiple sclero-
sis (MS) or rheumatoid arthritis (RA) [6,7], whereas
others, such as systemic lupus erythematodes;
mainly mediated by Th2 cytokines, have an unpre-
dictable course or tend to worsen during pregnancy
[8]. In contrast to the previously reported patients
with NMO who all experienced marked disease
exacerbation, our patient remained completely sta-
ble during pregnancy after treatment with rituxi-
mab just before inadvertent conception.
Treatment of autoimmune diseases during preg-
nancy and during the postpartum period is chal-
lenging. Corticosteroids and some immunosuppres-
sive drugs (e.g., azathioprine) are used, but may be
associated with complications such as preterm
delivery, low birth weight, and intrauterine growth
restriction [9]. Data on the safety of rituximab dur-
ing pregnancy are very limited. The Food and Drug
Administration classification is category C (risk can-
not be ruled out). In our patient, application of
rituximab 1–2 weeks before conception was fol-
lowed by clinical stabilization of her NMO during
the entire pregnancy and was not associated with
any abnormalities of the child.
Data on the postpartum course of NMO are also
lacking. In MS as well as in RA, the risk of relapse is
increased during the first months after delivery [7].
Postpartum application of intravenous immunoglo-
bulins (IVIg) has been recommended for patients
with high risk of MS [6]. However, the benefit of
Figure 1 This figure shows EDSS-score, B cells, and relapses (*) since disease onset. Application of rituximab (arrows) led to
B cell depletion. One relapse occured one week after delivery despite lasting depletion of B cells.
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IVIg in MS remains doubtful [10]. Our patient had a
relapse just 1 week after delivery despite lasting
depletion of her B–cells, 9 months after treatment
with rituximab. This indicates that other B-cell
independent mechanisms, such as proinflamma-
tory mediators or other types of immune cells,
might contribute to disease activity in patients
with NMO during the postpartum period. Whether
patients with NMO would also benefit from post-
partum IVIg prophylaxis is currently unknown.
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